NEW YORK, Aug 16: Amgen Inc, the drugmaker in advanced discussions to buy Onyx Pharmaceuticals Inc, has asked Onyx for some of the data from an ongoing trial on the company’s new blood cancer drug, two people familiar with the matter said yesterday. Amgen, the world’s largest biotechnology company, has questions about Onyx’s new blood cancer drug Kyprolis and wants access to some trial data to better evaluate the treatment, said the people, who wished to remain anonymous because the conversations are confidential. (agencies)
Trending Now
E-Paper
Follow our WhatsApp channel